TCR2 Therapeutics Inc. buy quelbe60
Start price
16.10.22
/
50%
€1.68
Target price
16.10.23
-
Performance (%)
-6.83%
End price
30.10.22
€1.56
Summary
This prediction ended on 30.10.22 with a price of €1.56. With a performance of -6.83%, the BUY prediction by quelbe60 finished with a loss. quelbe60 has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| TCR2 Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | -1.059% | 5.007% | 6.596% | 64.713% |
| iShares Nasdaq 100 | -2.387% | 0.864% | 25.791% | 88.244% |
| iShares Nikkei 225® | -4.361% | 1.211% | 41.309% | 79.311% |
| iShares S&P 500 | -1.778% | 1.391% | 21.037% | 69.603% |
According to quelbe60 what are the pros and cons of TCR2 Therapeutics Inc. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by quelbe60 for this prediction
In the thread Tcr2 Therapeutics Inc. diskutieren
Buy TCR2 Therapeutics Inc.